Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with
 generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive
 daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.
Inclusion Criteria:

 -  Diagnosis of gMG [Myasthenia Gravis Foundation of America (MGFA) Class II-IVa] at
 Screening

 -  Positive serology for acetylcholine receptor (AChR) autoantibodies

 -  QMG score ≥ 12 at Screening and Randomization

 -  No change in corticosteroid dose for at least 30 days prior to Randomization or
 anticipated to occur during the 12-week Treatment Period

 -  No change in immunosuppressive therapy, including dose, for at least 30 days prior to
 Randomization or anticipated to occur during the 12-week Treatment Period

 Exclusion Criteria:

 -  Thymectomy within 6 months prior to Randomization or scheduled to occur during the 12
 week Treatment Period

 -  History of meningococcal disease

 -  Current or recent systemic infection within 2 weeks prior to Randomization or
 infection requiring intravenous (IV) antibiotics within 4 weeks prior to Randomization